Molecular Therapeutics, Inc. (MRx) is a privately held biotechnology holding company that focuses on in-licensing promising pharmaceutical and medical device technologies in the late preclinical development phase and conducts proof-of-principle clinical (phase II) studies on a virtual basis for eventual corporate partnership and commercialization.